Latest:
Dr Tagawa on the Evaluation of Lutetium Lu 177 Rospatamab Tetraxetan Plus SOC in mCRPC
Scott T. Tagawa, MD, FASCO, FACP, MS, discusses the addition of lutetium 177Lu-rosopatamab tetraxetan to SOC in mCRPC.
Authors
Bruna Pellini, MD
Latest:
Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer
Dr. Bruna Pellini presents key data comparing real-world outcomes of atezolizumab versus durvalumab in extensive-stage small cell lung cancer (ES-SCLC), demonstrating a significant overall survival advantage and lower immune-related adverse events with durvalumab, while progression-free survival remained comparable between the two treatments.
Arutha Kulasinghe, PhD
Latest:
Dr Kulasinghe on a Study Profiling the NSCLC Tumor Microenvironment
Arutha Kulasinghe, PhD, discusses findings from a study profiling the tumor microenvironment of non–small cell lung cancer, as well as future directions planned with this research and the implications of these findings.
Beth N. McLellan, MD
Latest:
Dr McLellan on the Association Between A Skin Bacterium and Severe Acute Radiation Dermatitis
Beth N. McLellan, MD, discusses the use of a low-cost, topical treatment to prevent severe cases of acute radiation dermatitis potentially caused by the skin bacterium Staphylococcus aureus in breast cancer.
Judith Karp, MD
Latest:
Women in Oncology: Leukemia Therapies in Humans, for Humans
Judith Karp, MD, Azra Raza, MD, and Michelle M. Le Beau, PhD, discuss their proudest career accomplishments, including the investigation of potential treatments using a patient’s first cancerous cell, advances in cytogenetics, and a rational design for clinical trials involving cell cytokinetics..
Suzanne Mahon DNS, RN, AOCN, AGN-BC, FAAN
Suzanne Mahon, DNS, RN, AOCN®, AGN-BC, FAAN, is a professor emeritus at Saint Louis University in Missouri.
Latest:
Dr Mahon on the Importance of Integrating Genomic Science Into Oncology Practice
Suzanne Mahon DNS, RN, AOCN, AGN-BC, FAAN, discusses the importance of integrating genomic science into oncology practice.
Monzr M. Al Malki, MD
Monzr M. Al Malki, MD, is an associate professor in the Division of Leukemia and Hematopoietic Cell Transplantation, director of Unrelated Donor BMT Program, and director of Haploidentical Transplant Program at City of Hope.
Latest:
Drs Al Malki and Auletta on PTCy GVHD Prophylaxis in Patients With HLA-UUMD
Monzr Al Malki, MD and Jeffery J. Auletta, MD discuss evaluating PTCy-based GVHD prophylaxis in hematologic malignancies.